Form 4: Twist Bioscience COO Sells Shares for Tax Obligations

Twist Bioscience's President and COO, Patrick John Finn, sold 2,390 shares of common stock at $44.908 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a transaction involving the company's common stock.
• On January 23, 2026, Finn disposed of 2,390 shares of common stock at a price of $44.908 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• This transaction was mandated by the Issuer's equity incentive plans as a 'sell to cover' requirement and was not a discretionary trade by Mr. Finn.
• Following this transaction, Mr. Finn beneficially owns 310,493 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary sale to cover tax withholding obligations, rather than a voluntary sale indicating a change in the executive's outlook on the company.

Negatives

• The transaction resulted in a reduction of 2,390 shares from the direct beneficial ownership of a key executive.

Future Outlook

NA

Management Comments

• The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This filing is a routine disclosure of an insider transaction, specifically a 'sell to cover' for tax purposes, which is a common practice in executive compensation plans across various industries, particularly in high-growth biotech companies like Twist Bioscience.

Comparison to Industry Standards

• The 'sell to cover' mechanism for tax withholding is a standard practice in equity compensation plans across many publicly traded companies, aligning with common industry benchmarks for managing RSU vesting and associated tax liabilities.
• The transaction is consistent with typical insider reporting requirements for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature of the sale mitigates concerns about executive confidence.
• Employees: No direct impact on employees beyond the executive involved.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell to cover' transaction by a key executive to satisfy tax obligations related to RSU vesting. Such transactions are common and generally do not reflect a change in the executive's confidence in the company's future prospects. Therefore, this specific filing alone does not provide sufficient new information to warrant a change in investment recommendation, maintaining a 'hold' stance based on existing fundamentals.

Keywords

Twist Bioscience, TWST, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Executive Compensation